Progressive Multiple Cystic Changes in Both Lungs in a Patient Treated with Gefitinib for Lung Adenocarcinoma with Multiple Lung Metastases.
10.3348/kjr.2014.15.2.300
- Author:
Yon Ju RYU
1
;
Eun Mi CHUN
;
Soon Nam LEE
;
Sung Shin SHIM
Author Information
1. Division of Pulmonary and Critical Care Medicine, Ewha Womans University School of Medicine, Seoul 158-710, Korea. cem@ewha.ac.kr
- Publication Type:Case Reports
- Keywords:
Gefitinib;
Non-small cell lung cancer;
Cystic change
- MeSH:
Antineoplastic Agents/*adverse effects;
Brain Neoplasms/secondary;
Carcinoma, Non-Small-Cell Lung/*drug therapy/secondary;
Cysts/*chemically induced;
Female;
Humans;
Lung/pathology;
Lung Diseases/*chemically induced;
Lung Diseases, Interstitial;
Lung Neoplasms/*drug therapy;
Middle Aged;
Quinazolines/*adverse effects
- From:Korean Journal of Radiology
2014;15(2):300-304
- CountryRepublic of Korea
- Language:English
-
Abstract:
Gefitinib is regarded as a relatively safe agent for the treatment of an advanced non-small cell lung cancer (NSCLC). Pulmonary toxicity such as interstitial lung disease associated with gefitinib is uncommon with an estimated all time incidence around 1% worldwide. Moreover, a case of gefitinib associated with pulmonary cystic changes has not been reported yet. In this report we present a case of progressive multiple air cystic changes in both lungs in a patient with NSCLC and intrapulmonary metastases who underwent a gefitinib therapy.
